Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Cyclooxygenase inhibition corrects the impaired microvascular reactivity in diabetic female rats

  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care20037 (Suppl 3) :P120

https://doi.org/10.1186/cc2316

  • Published:

Keywords

  • Histamine
  • Bradykinin
  • Peripheral Vascular Disease
  • Platelet Activator Factor
  • Cyclooxygenase Inhibition
Several studies have shown that endothelium-dependent vascular relaxation is altered in experimental diabetes and in diabetic patients, with peripheral vascular disease being almost twice as frequent in diabetic women as compared with diabetic men. Moreover, the mesenteric microvessels exhibit impaired responses to acetylcholine, bradykinin, histamine, and platelet activator factor in diabetic female rats. The aim of the present study was to investigate the effects of inhibition of cyclooxygenase upon the reduced response to endothelium-dependent vasodilator agents in diabetic female rats, to verify the possible involvement of prostaglandins in that alteration. The changes of arteriolar and venular diameter after topical application of acetylcholine (17 nmol), bradykinin (30 pmol), and histamine (2.7 nmol) were measured in vivo by means of a closed video circuit coupled to a microscope before and after acute treatment with diclofenac, a cyclooxygenase inhibitor (2.5 mg/kg, intramuscularly). The cyclooxygenase inhibition corrected the decreased response of arterioles and venules to bradykinin, but only corrected the decreased venular response to acetylcholine. Diabetes impaired the response to histamine in arterioles but not in venules, and that response reduction was also corrected by diclofenac (see Table 1). These data suggest that increased release of vasoconstrictor prostanoids may be involved in the impaired response to endothelium-dependent vasodilator agents in diabetic female rats.
 

Arterioles

Venules

 

Acetylcholine

Bradykinin

Histamine

Acetylcholine

Bradykinin

Histamine

Control

6.9 ± 0.7

7.5 ± 0.6

7.8 ± 0.2

6.5 ± 0.6

6.7 ± 0.7

6.8 ± 0.5

Diabetes

4.1 ± 0.5*

4.2 ± 0.5*

4.1 ± 0.6*

3.6 ± 0.3*

4.2 ± 0.6*

4.7 ± 1.0

Diabetes + diclofenac

5.8 ± 0.4

7.8 ± 1.0

6.6 ± 0.5

5.8 ± 0.5

6.7 ± 0.5

5.1 ± 0.9

*P < 0.05 in comparison with controls, P < 0.05 in comparison with the diabetic + diclofenac group.

Declarations

Acknowledgements

Financial support from FAPESP and PRONEX.

Authors’ Affiliations

(1)
Department of Pharmacology, Institute of Biomedical Sciences, USP, São Paulo, SP, Brazil

Copyright

Advertisement